Scientists from the Neurological Sciences Institute at Oregon Health & Science University have shown that an investigative drug for multiple sclerosis and related diseases prevented disease development when tested on animal models. The drug, LGD5552, prevented rats from developing a well-established animal model of MS. San Diego-based Ligand Pharmaceuticals Inc. collaborated in, and funded, the study. The results are being presented today at Endo 2004, the national meeting of The Endocrine Society in New Orleans, La.
